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Abstract N Opioid receptors were identified in human melano-
mas by RT-PCR and radioligand binding. In all tumors an
additional PCR amplificate was detected in which 144 bp within
the third exon were deleted. This fragment corresponded to the
third cytoplasmic domain of the receptor protein. The short
variant resulted from atypical mRNA processing. There were no
common splice recognition sequences around the deleted frag-
ment; instead its excision resembled the removal of a transposon.
The deletion was not detected in normal human melanocytes nor
in human or rat brain. However, it was present in a human
neuroblastoma cell line (SH-SY5Y). Thus, it appears that the
occurrence of the short N opioid receptor is correlated to
malignancy. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
N Opioid receptors, along with W and U, belong to the family
of neuropeptide receptors which respond to endogenous
opioid peptides [1]. They are mainly found in the central
and peripheral nervous system. However, in the dermis of
frogs opioid peptides with a high selectivity for N or W recep-
tors were detected and called deltorphins and dermorphins,
respectively [2,3]. There is evidence for a local opioid system
in human skin, too. The presence of opioid binding sites has
been reported [4] as well as e¡ects of opioids on human ker-
atinocytes [5]. Furthermore, the opioid peptide L-endorphin
was found in cultured human epidermal cells [6,7] as well as
the mRNA for its precursor proopiomelanocortin (POMC)
[8]. Correspondingly, binding sites for L-endorphin became
evident on human keratinocytes [9]. The epidermal part of
the human skin mainly consists of keratinocytes. A small
fraction is made up of melanocytes which are sending out
dendrites around which a group of several keratinocytes is
located to receive melanophores from the former [10]. In
this work the presence of N opioid receptors in normal human
melanocytes will be demonstrated.
The rat N opioid receptor was cloned in 1992 [11,12], and
the human form was published 2 years later along with its
genomic organization [13]. The coding region consists of three
exons separated by two introns, 46.3 kb and 3.4 kb long. Each
of these introns is £anked by the usual splice donor and ac-
ceptor sequences, i.e. GT followed by purines at the 5P ends
and AG preceded by a pyrimidine-rich stretch at the 3P ends
[14^16]. In the present study it will be shown that in certain
tumor cells an atypical mRNA processing takes place which
does not involve such motifs.
2. Materials and methods
2.1. Reagents
Cell culture reagents were from Gibco, and enzymes for molecular
biology including reaction bu¡ers were from Hybaid-AGS (Heidel-
berg, Germany) unless stated otherwise. The opioid receptor ligands
DPDPE (cyclic [D-penicillamine2,D-penicillinamine5]) enkephalin) and
DAMGO ([D-Ala2,MePhe4,Gly-ol5] enkephalin) were from Bachem,
Heidelberg, Germany, and U 69 593 ((5K,7K,8L)-(+)-N-methyl-N-(7-
[1-pyrrolidinyl]-1-oxaspiro[4,5]dec-8-yl)-benzeneacetamide) was from
Sigma, Deisenhofen, Germany. The corresponding radiolabeled li-
gands were from NEN Life Science Products, Boston, MA, USA.
2.2. Cell culture
Primary human normal melanocytes prepared as described previ-
ously [17,18] were a generous gift from Dr. S. Kippenberger, Frank-
furt/Main, Germany. The cells were received at the 11th passage and
kept for further passages in our laboratory in Ham’s F10 medium
supplemented with 5% fetal calf serum (FCS), 85 nM TPA (4-O-
methyl-12-O-tetradecanoylphorbol-13-acetate), 0.1 mM isobutylme-
thylxanthine (IBMX) and 0.1 nM cholera toxin in a water-saturated
atmosphere at 37‡C and 5% CO2. G361 cells (ECACC, Salisbury,
UK) were cultured in McCoy’s 5A medium containing 10% FCS,
the lines COLO 679 (ECACC, Salisbury, UK) and COLO 800
(DSMZ, Braunschweig, Germany) were kept in RPMI 1640 medium
supplemented with 10% FCS under the same atmospheric and temper-
ature conditions as the melanocytes. SH-SY5Y neuroblastoma cells
(DSMZ, Braunschweig, Germany) were grown in DMEM medium
containing 15% FCS.
2.3. Radioligand binding assay
2.3.1. Membrane preparation. Crude membrane fractions were
prepared following described protocols [19,20] with minor modi¢ca-
tions. All steps were carried out at 0^4‡C. G361 cells grown to con-
£uency on petri dishes were washed twice with homogenization bu¡er
(10 mM Tris^HCl, pH 7.4, 0.3 M sucrose) and scraped o¡ in this
bu¡er containing a protease inhibitor mix (0.01% aprotinin, 1 mM
PMSF, 10 Wg/ml leupeptin, 50 Wg/ml bacitracin, 10 Wg/ml soybean
trypsin inhibitor). Homogenization was performed in a glass^te£on
homogenizer by 20 strokes. The homogenate was centrifuged at
200Ug for 5 min to remove nuclei and cell debris; the supernatant
was centrifuged twice at 38 000Ug for 20 min. The resulting pellet
represented the crude membrane preparation. It was processed imme-
diately or was stored at 380‡C until use.
2.3.2. Binding assay. G361 cell membranes were incubated in
binding bu¡er (0.5 mM MgCl2, 2.7 mM KCl, 140 mM NaCl,
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1.5 mM KH2PO4, 8.1 mM Na2HPO4), containing 0,1% BSA and the
protease inhibitor mix described above, together with one of the la-
beled ligands, [3H]DPDPE, [3H]DAMGO or [3H]U69593 in concen-
trations of 2.2, 1.8 and 2.5 nM, respectively. To determine non-spe-
ci¢c binding to the membranes, part of the samples also contained the
corresponding unlabeled ligand in a concentration of 20 WM unless
stated otherwise. Samples (100 Wl) were incubated for 120 min on ice;
then free radioactivity was removed by sample ¢ltration through GFB
glass ¢ber ¢lters (Whatman-Biometra, Go«ttingen, Germany) which
had been pre-soaked in 0,1% polyethylenimine at room temperature
for 3 h. Filters were washed three times with 3 ml ice-cold binding
bu¡er containing 0.01% Triton X-100. The ¢lters were transferred to
scintillation vials, and radioactivity was determined by liquid scintil-
lation counting. Samples were run in triplicate; membranes from
3U107 cells were used per sample.
2.4. RNA extraction and PCR ampli¢cation
Total RNA was extracted obeying standard protocols using guani-
dinium thiocyanate and sodium lauryl sulfate in citrate bu¡er for
lysing the cells or tissue followed by phenol^chloroform treatment
and ethanol precipitation. This RNA preparation also served as a
template for genomic PCR because it contained su⁄cient DNA. To
prevent ampli¢cation of the latter in the RT-PCR setups, all PCR
primer pairs intended for amplifying cDNA spanned at least one
intron which excluded genomic ampli¢cation. Complementary DNA
was reverse-transcribed from total cellular RNA by using random
hexanucleotide primers. Reactions were performed for 15 min at
18‡C and then for 2 h at 42‡C. The total reaction volume was 20 Wl
which contained 90 U of enzyme and 1^3 Wg of RNA. Four micro-
liters of this reaction mixture were used as a template for PCR am-
pli¢cation. The total PCR reaction volume was 20 Wl. The reaction
mixture consisted of PCR bu¡er (Appligene, Heidelberg, Germany,
for Taq polymerase or Promega, Mannheim, Germany, for Pfu poly-
merase), 0.2 mM of each dNTP, 4 pmol of each primer and 0.8 units
of Taq or Pfu (Promega, Mannheim, Germany) DNA polymerase.
The following primers were used, an overview is also given in Fig. 1.
Primer 1: 5P-CAA GGC CCT GGA CTT CCG CA, position 462;
primer 2: 5P-TCC CAA GCC TCC GAC CTT CTA CTG, position
1234, complementary strand. PCR conditions for this primer pair:
2 mM MgCl2, annealing temperature 66‡C.
Primer 3: 5P-GCC AAG CTG ATC AAC ATC TG, position 493;
primer 4: 5P-AAG CAG CGC TTG AAG TTC TC, position 986,
complementary strand; primer 5: 5P-ACC AAG ATC TGC GTG
TTC CT, position 637. PCR conditions for the primer combination
3/4: 1.5 mM MgCl2, annealing temperature 58‡C; conditions for
primer combination 5/4: 2 mM MgCl2, annealing temperature 58‡C.
Primer 3a: 5P-GTT GGC GTG CCC ATC ATG GT, position 535;
primer 4a: 5P-GAA GTT CTC GTC GAG GAA AGC GTA G,
position 975, complementary strand. This primer pair was used for
nested reampli¢cation of primers 3/4 ampli¢cates. PCR conditions for
3a/4a: 2 mM MgCl2, annealing temperature 68‡C.
Primer 7: 5P-GGG CTG CTG GGC AAC GTG CT, position 187;
primer 8: 5P-CCA GAC GAT GAC GAA GAT GTG GAT GG,
position 852, complementary strand; primer 9: 5P-AAG CAG CCG
GTG GAG AGG GAC, position 340. PCR conditions for primers
7/8: 1.5 mM MgCl2, annealing temperature 72‡C; conditions for
primers 9/8: 3 mM MgCl2, annealing temperature 72‡C.
Further primers used for genomic ampli¢cation £anked the third
exon [21], or the left (5P) primer was placed in the intron upstream of
exon 3. All PCR reactions started with a denaturation step of 3 min at
95‡C followed by 40 cycles, 50 s 95‡C, 90 s annealing (at the temper-
atures stated above) and elongation at 72‡C for 3^6 min, depending
on the length of the PCR product.
3. Results
3.1. N Opioid receptors in pigment cells
Three human melanoma cell lines, G361, COLO 679 and
COLO 800, were screened by RT-PCR for the presence of
N opioid receptor mRNA. The primers used, called primer 1
and 2, spanned about two thirds of the coding region includ-
ing the stop codon (Fig. 1 gives a schematic representation of
the N receptor mRNA and the position of the primers used).
From all three cell lines a PCR product of the expected
length, 773 bp, could be created (Fig. 2A). Remarkably, an
additional band, approximately 150 bp shorter, was present in
all cases (see Section 3.2).
To con¢rm that the N receptor mRNA from these pigment
cells contained the complete coding region, three further prim-
ers were employed. They were called primer 7, 8 and 9, re-
spectively, and were combined to two pairs, 7/8 and 9/8 (Fig.
1). The resulting ampli¢cates encompassed the 5P-part of the
coding region and the site of the deletion. In either case an
ampli¢cation product of the correct length was obtained along
with a band approximately 150 bp smaller. This ¢nding in-
dicates that pigment cells express the complete message for the
N opioid receptor and that the short form does not display
further deletions. To exclude the possibility that the short
fragment originated from a reading error of Taq polymerase,
PCR reactions were also performed with Pfu polymerase
which possesses proof-reading activity and therefore a lower
Fig. 1. Schematic representation of the N opioid receptor cDNA along with the positions of the PCR primers used. PCR primers are shown as
arrowheads. Primer pair 3a/4a used for nested reampli¢cation is not indicated; it is located close to primers 3 and 4. Below the horizontal axis
the length and position of the three ampli¢cates created by the primers displayed are shown to scale.
FEBS 24044 28-8-00
P. Mayer et al./FEBS Letters 480 (2000) 156^160 157
error rate. An example for an ampli¢cation of cDNA from
G361 cells using Pfu polymerase and primer pair 7/8 is given
in Fig. 2B. Again, both bands were observed.
The presence of functional opioid receptors on pigment
cells was demonstrated by ligand binding studies. They were
performed with membranes of G361 cells, and tritium-labeled
opioid agonists selective for W, N or U receptors were employed
(see Section 2 for details). Speci¢c and reversible binding was
detected with the N receptor ligand DPDPE. Radioligand
competition studies with increasing concentrations of unla-
beled DPDPE (Fig. 2C) revealed a dissociation constant Kd
of 6.2 nM (mean of three experiments). This value is in good
accordance with reported Kd values for DPDPE on N opioid
receptors [11,12,22]. The receptor density was in the range of
10 fmol/mg protein, which is lower than the values reported
for e.g. SH-SY5Y cells (around 35 fmol/mg protein according
to [23] and in the range of 100 fmol/mg protein according to
[24]). No speci¢c binding was detected with the W receptor
speci¢c ligand DAMGO nor with the U ligand U 69 593
(not shown).
3.2. Distribution of the short form of N opioid receptors in
pigment and neuronal cells
Further cells and tissues were screened for the expression of
the novel short form of the N opioid receptor, namely normal
human melanocytes [17,18], rat and human brain, a native
human melanoma metastasis obtained from a Caucasian pa-
tient and a human neuroblastoma cell line (SH-SY5Y). Fig.
3A gives an overview of the results. The normal N opioid
receptor, identi¢ed by a 500 bp ampli¢cate (primer pair 3/4),
was present in all cases. The short form (350 bp ampli¢cate),
however, was exclusively detected in melanoma and neuro-
blastoma cells, i.e. in all malignant tumors tested. On the
other hand, neither normal melanocytes nor normal brain
did express the short variant. Several areas of the rat cere-
brum were tested (frontal cortex is shown in Fig. 3A) as well
Fig. 2. Detection of N opioid receptors in pigment cells by RT-PCR
and by ligand binding. A: RT-PCR: primer pair 1/2 was used. As a
control for contamination, reverse transcription reaction mixtures
were set up omitting the enzyme (indicated as ‘3rt’). The cells lines
tested are indicated. ‘M’ denotes the size marker lane. B: RT-PCR
using proof-reading Pfu polymerase: to exclude reading errors by
Taq polymerase as the cause of the smaller N receptor band, Pfu in-
stead of Taq polymerase was used to amplify a N opioid receptor se-
quence from G361 cDNA (primer pair 7/8). C: Ligand binding:
competition curve, displaying the inhibition of [3H]DPDPE binding
to G361 cell membranes by 10310^1034 M concentrations of unla-
beled DPDPE. [3H]DPDPE binding is given in percent of control,
i.e. [3H]DPDPE binding in the absence of cold ligand. Each data
point represents the mean þ S.E.M. of three independent experi-
ments.
Fig. 3. Occurrence and origin of the short N opioid receptor variant.
A: Expression in di¡erent cell types: the primer pair 3/4 was used
to screen the cell lines and tissues as indicated. The band at around
500 bp corresponds to the ‘wild type’ receptor. Correspondingly, the
shorter form migrated at around 350 bp. ‘Melanocytes’ means pri-
mary cultured normal human melanocytes; COLO 679, G361,
COLO 800 are three di¡erent human melanoma cell lines, and ‘mel-
anoma’ indicates a native human melanoma metastasis obtained by
surgery; ‘brain’ stands for rat frontal cortex. SH-SY5Y is a human
neuroblastoma cell line. The omission of reverse transcriptase (‘3rt’)
served as a control to rule out PCR contamination. ‘M’ denotes the
size marker. B: Reampli¢cation of selected samples from A, the
nested primers 3a and 4a were used for reampli¢cation to avoid
overlooking small amounts of the short N receptor in non-malignant
tissues (melanocytes and human temporal cerebral cortex). For com-
parison, the result for the melanoma line COLO 679 is also shown.
C: Genomic PCR ampli¢cation: the primers 4 and 5 were used
which produce a 350 bp ampli¢cate from the wild type sequence.
‘M’ denotes size marker, ‘melanoma’ is the same melanoma tissue
as in A. Water as template served to exclude PCR contamination.
Note that no additional band is visible indicating that the genome
contains no sequence corresponding to the shorter form of the N re-
ceptor.
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as human temporal cortex (Fig. 3B), and in no case the short
N receptor mRNA was detected. To exclude that the latter was
overlooked in non-malignant tissue because of low abun-
dance, we performed reampli¢cation reactions with nested
primers (primers 3a and 4a) using PCR products obtained
with the primers 3/4 as templates (Fig. 3B). This experiment
clearly con¢rmed the absence of abnormal N receptor mRNA
in non-malignant cells.
3.3. Origin of the short N opioid receptor variant
In order to investigate how the short N opioid receptor is
produced, genomic DNA was ampli¢ed in search for aberra-
tions within the N receptor gene (Fig. 3C). Only a single PCR
product was obtained for each sample, and this product had
the length that was expected for the normal receptor (350 bp).
Also, it revealed no sequence abnormalities. This means that
the short N receptor form is not encoded in the genome; con-
sequently, it must have been produced by mRNA processing.
Nucleotide sequencing of the short receptor cDNA revealed a
deletion of 144 nucleotides (bases 673^816, Fig. 4A) within
the third exon. The length and position of the deletion were
identical in all samples tested. No other mutations were de-
tected. No frame shift resulted from this deletion. Therefore,
the receptor protein can be predicted to carry a deletion of 48
amino acids.
The N opioid receptor belongs to the family of G-protein
coupled receptors which possess seven transmembrane do-
mains. It can be derived from published data [13] that the
missing 48 amino acids exactly correspond to the third cyto-
plasmic domain of the receptor molecule (Fig. 4B). Remark-
ably, no splice consensus motifs were found at the respective
ends of the deleted fragment. Instead, another feature became
evident at the boundaries of the deletion. The region to be
excised was £anked by two copies of a 13 bp nucleotide
stretch (CGCCTTCGTGGTG, boxed in Fig. 4A). One of
these copies became deleted during the removal of the 144
bp fragment whereas the other remained in place (Fig. 4A).
Insertion of a nucleotide sequence by doubling several bases
at the insertion site and then removing the sequence again by
undoing the duplication is the mechanism by which all known
transposable DNA elements (transposons) enter a site of ge-
nomic DNA and leave it again [25]. Thus, a similar mecha-
nism seems to be at work in the case of the N opioid receptor.
4. Discussion
The results described above demonstrated the existence of a
to date unidenti¢ed variant of the N opioid receptor which is
generated by atypical mRNA processing, and the occurrence
of which is correlated with malignancy. The variant lacked
144 nucleotides, which corresponded to the third cytoplasmic
loop of the receptor protein, and was found exclusively in
malignant cells. The position and length of the deletion was
the same in all tumors tested, and other variations were not
found. These observations make it unlikely that the excision
of 144 bp is due to undirected mRNA processing in malignant
cells. Other variants of N and U opioid receptors were reported
recently [26]. In this case, however, the receptor proteins were
truncated, and the cause was clearly alternative splicing. To
date, no information about the physiological or pathophysio-
logical role of these receptor fragments is available.
The structure^function relationships of G-protein coupled
receptors, to which family the N opioid receptor belongs, are
quite well understood. It its known for G-protein coupled
receptors in general that the third cytoplasmic loop is involved
in G-protein coupling and in receptor desensitization after
chronic agonist stimulation [27]. Studies dealing with the
N opioid receptor revealed a potential ligand binding site in
the third extracellular loop extending into the sixth transmem-
brane domain [22,28,29], depicted schematically in Fig. 4B.
Fig. 4. Position of the 144 bp deletion in N opioid receptor cDNA and its putative implications for the receptor molecule structure. A: Shows
the human N opioid receptor cDNA sequence surrounding the deletion site (nucleotide position 673^816). Upper line: ‘wild type’ sequence; the
fragment to be deleted is indicated. The lower line shows the resulting cDNA sequence after removal of the 144 bp stretch. Boxed are the 13
bp motifs that are £anking the deletion site on both sides. B: The molecular structure of the N opioid receptor protein is depicted schemati-
cally. The small hatched boxes within the peptide chain indicate the positions that correspond to the 13 bp motifs boxed in part A. Left: wild
type receptor, right: short form.
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The ligand binding site is localized immediately adjacent to
the third cytoplasmic loop. Therefore, signal^response cou-
pling could be a¡ected. Alternatively, the truncated N receptor
may act by heterodimerization or hetero-oligomerization with
the wild type form and thereby disturb the function of the
latter as recently described for mutated D2 dopamine recep-
tors [30]. Melanocytes could be exceptionally sensitive to any
disturbance of intracellular signaling since keeping them in
culture requires the permanent activation of intracellular sig-
naling pathways by TPA, IBMX and cholera toxin added to
the culture medium [31,32]. It is known that mutated signaling
molecules (e.g. GsK) are able to induce tumor growth [33,34].
Thus, further studies will reveal whether the short N receptor
is involved in tumor genesis.
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